The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Study Results for 9 New Psoriatic Arthritis Drugs

Study Results for 9 New Psoriatic Arthritis Drugs

June 21, 2018 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
kenary820 / shutterstock.com

kenary820 / shutterstock.com

CHICAGO—As Eric Ruderman, MD, professor of medicine in rheumatology at Northwestern University Feinberg School of Medicine in Chicago, began his talk on psoriatic arthritis treatment at the ACR State-of-the-Art Clinical Symposium in April, he marveled a bit at how much there was to cover. Drugs gaining prominence in the treatment of rheumatoid arthritis and dermatological diseases have begun to carry over into psoriatic arthritis (PsA) research, where many have proved effective.

You Might Also Like
  • Apremilast Effective for Psoriatic Arthritis
  • Ustekinumab Improves Spondylitis in Patients with Psoriatic Arthritis
  • Approval Expected for Apremilast
Explore this issue
June 2018
Also by this Author
  • 2015 ACR/ARHP Annual Meeting: Behçet’s Disease Poses Diagnosis, Treatment Challenges

“Just a year ago, this talk would have had a lot less involved,” he said.

Biologics are being assessed in PsA at a rapid rate—some with persuasive data, some in small but tantalizing samples, Dr. Ruderman said. As new therapies undergo testing, he said, it’s important to consider how they affect the array of disease manifestations.

“This is not just about joints,” he said. “This is a disease that’s about joints, it’s about skin, it’s about enthesitis, it’s about dactylitis, it’s about nail disease. So many other pieces.”

Dr. Ruderman spoke about several therapies, including apremilast, tofacitinib, abatacept, ustekinumab, ixekizumab, secukinumab, bimekizumab, risankizumab and guselkumab.

Apremilast

This drug—which targets cyclic adenosine monophosphate (cAMP), a regulator of several key immune pathways—works for enthesitis and dactylitis, “[a]nd the drug works quickly. We’re used to that with these targeted small molecules,” Dr. Ruderman said. Effects were seen within two to four weeks.1

He advised clinicians not to misinterpret the drug’s ACR 20% score (ACR20) response rate of 40%. “One thinks, ‘Well, that’s not so good.’… Be careful about assuming that means this drug works less well in the people in whom it works. I think what it really means is, this drug works in fewer people. … The people who respond, some of them actually respond pretty well.”

Importantly, he said, “you’re not seeing the immunosuppressive effects [with apremilast] that raise concern for infections [that] we see with some of the biologic agents we’ve been concerned about.”

More data are needed to sort through what can be confusing options, Dr. Ruderman said. ‘We need good comparative efficacy studies.’

Tofacitinib

This JAK1 and JAK3 inhibitor has been the subject of two PsA trials in the last year, and it was recently approved for PsA. “The tofacitinib response was in the same order of magnitude as we’re used to seeing with adalimumab” among inadequate responders to conventional disease-modifying anti-rheumatic drugs (DMARDs), he said.2

Abatacept

This therapy, which binds CD80 and CD86, produced a “modest” ACR20 response rate of 40%, but it was still superior to placebo and is another option for patients who fail earlier treatments. The response on skin was not impressive, Dr. Ruderman said.

Pages: 1 2 3 Single Page

Filed Under: Conditions, Drug Updates, Systemic Inflammatory Syndromes Tagged With: abatacept, apremilast, Bimekizumab, guselkumab, ixekizumab, psoriatic arthritis, risankizumab, secukinumab, Tofacitinib, ustekinumabIssue: June 2018

You Might Also Like:
  • Apremilast Effective for Psoriatic Arthritis
  • Ustekinumab Improves Spondylitis in Patients with Psoriatic Arthritis
  • Approval Expected for Apremilast
  • Secukinumab Effective for Treating Psoriatic Arthritis

Comments

  1. Kathy says

    January 16, 2019 at 5:38 pm

    Can the biologic Taltz be combined with Xelganz?

    Reply
    • Keri Losavio says

      January 16, 2019 at 6:02 pm

      Please check with your rheumatologist and pharmacist.

      Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

ACR/ARP Meeting Abstracts

Browse and search abstracts from the ACR/ARP Annual Meetings going back to 2012.

Visit the ACR/ARP Meeting Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.